-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head-To-Head Comparison: Avantor (NYSE:AVTR) & Seer (NASDAQ:SEER)
Head-To-Head Comparison: Avantor (NYSE:AVTR) & Seer (NASDAQ:SEER)
Avantor (NYSE:AVTR – Get Rating) and Seer (NASDAQ:SEER – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.
Analyst Ratings
This is a summary of current recommendations and price targets for Avantor and Seer, as provided by MarketBeat.com.
Get Avantor alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Avantor | 0 | 4 | 10 | 0 | 2.71 |
Seer | 0 | 2 | 1 | 0 | 2.33 |
Avantor currently has a consensus target price of $33.43, suggesting a potential upside of 67.06%. Seer has a consensus target price of $13.00, suggesting a potential upside of 65.39%. Given Avantor's stronger consensus rating and higher probable upside, equities analysts plainly believe Avantor is more favorable than Seer.
Earnings & Valuation
This table compares Avantor and Seer's top-line revenue, earnings per share and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Avantor | $7.39 billion | 1.83 | $572.60 million | $0.93 | 21.52 |
Seer | $6.62 million | 74.14 | -$71.17 million | ($1.37) | -5.74 |
Avantor has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Avantor has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.
Institutional and Insider Ownership
81.2% of Avantor shares are owned by institutional investors. Comparatively, 75.9% of Seer shares are owned by institutional investors. 1.6% of Avantor shares are owned by insiders. Comparatively, 18.0% of Seer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Avantor and Seer's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Avantor | 8.27% | 27.14% | 7.18% |
Seer | -695.94% | -17.12% | -16.03% |
Summary
Avantor beats Seer on 11 of the 14 factors compared between the two stocks.
About Avantor
(Get Rating)
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
About Seer
(Get Rating)
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
Avantor (NYSE:AVTR – Get Rating) and Seer (NASDAQ:SEER – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.
埃文特(NYSE:AVTR-GET Rating)和賽爾(納斯達克:SEER-GET Rating)都是醫藥公司,但哪隻股票更好?我們將根據這兩家公司的估值、風險、收益、機構所有權、分析師建議、盈利能力和股息的實力進行比較。
Analyst Ratings
分析師評級
This is a summary of current recommendations and price targets for Avantor and Seer, as provided by MarketBeat.com.
這是MarketBeat.com提供的對Avantor和Seer的當前建議和目標價的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Avantor | 0 | 4 | 10 | 0 | 2.71 |
Seer | 0 | 2 | 1 | 0 | 2.33 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
復仇者 | 0 | 4 | 10 | 0 | 2.71 |
先知 | 0 | 2 | 1 | 0 | 2.33 |
Avantor currently has a consensus target price of $33.43, suggesting a potential upside of 67.06%. Seer has a consensus target price of $13.00, suggesting a potential upside of 65.39%. Given Avantor's stronger consensus rating and higher probable upside, equities analysts plainly believe Avantor is more favorable than Seer.
Avantor目前的共識目標價為33.43美元,暗示潛在上行67.06%。Seer的普遍目標價為13.00美元,暗示潛在上漲65.39%。考慮到Avantor更高的共識評級和更高的可能上行空間,股票分析師顯然認為Avantor比Seer更有利。
Earnings & Valuation
收益與估值
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Avantor | $7.39 billion | 1.83 | $572.60 million | $0.93 | 21.52 |
Seer | $6.62 million | 74.14 | -$71.17 million | ($1.37) | -5.74 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
復仇者 | 73.9億美元 | 1.83 | 5.726億美元 | $0.93 | 21.52 |
先知 | 662萬美元 | 74.14 | -7,117萬美元 | ($1.37) | -5.74 |
Avantor has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.
Avantor的收入和收益比Seer更高。Seer的市盈率低於Avantor,這表明它目前是兩隻股票中更負擔得起的一隻。
Volatility and Risk
波動性和風險
Avantor has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.
Avantor的貝塔係數為1.34,這表明其股價的波動性比標準普爾500指數高34%。相比之下,Seer的貝塔係數為1.74,這表明其股價的波動性比標準普爾500指數高出74%。
Institutional and Insider Ownership
機構和內部人持股
81.2% of Avantor shares are owned by institutional investors. Comparatively, 75.9% of Seer shares are owned by institutional investors. 1.6% of Avantor shares are owned by insiders. Comparatively, 18.0% of Seer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Avantor 81.2%的股份由機構投資者持有。相比之下,SEER 75.9%的股份由機構投資者持有。Avantor 1.6%的股份由內部人士持有。相比之下,Seer 18.0%的股份由內部人士持有。強大的機構持股表明,對衝基金、大型基金管理公司和捐贈基金相信,一隻股票有望實現長期增長。
Profitability
盈利能力
This table compares Avantor and Seer's net margins, return on equity and return on assets.
下表比較了埃文特和賽爾的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Avantor | 8.27% | 27.14% | 7.18% |
Seer | -695.94% | -17.12% | -16.03% |
淨利潤率 | 股本回報率 | 資產回報率 | |
復仇者 | 8.27% | 27.14% | 7.18% |
先知 | -695.94% | -17.12% | -16.03% |
Summary
摘要
Avantor beats Seer on 11 of the 14 factors compared between the two stocks.
在兩隻股票比較的14個因素中,埃萬託有11個擊敗了Seer。
About Avantor
關於Avantor
(Get Rating)
(獲取評級)
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Avantor,Inc.為美洲、歐洲、亞洲、中東和非洲的生物製藥、醫療保健、教育和政府、先進技術和應用材料行業的客户提供產品和服務。該公司提供材料和消耗品,如純度化學品和試劑、實驗室產品和用品、配方硅材料、定製輔料、定製一次性組件、過程色層樹脂和色譜柱、分析樣品製備試劑盒、教育和微生物學產品、臨牀試驗試劑盒、蠕動泵和流體處理提示。它還提供設備和儀器產品,包括過濾系統、病毒滅活系統、孵化器、分析儀器、蒸發器、超低温冰櫃、生物安全櫃和關鍵環境用品。此外,該公司還提供服務和專業採購,包括現場實驗室和生產、臨牀、設備、採購和採購,以及生物製藥材料的擴大和開發服務。Avantor,Inc.成立於1904年,總部設在賓夕法尼亞州拉德諾市。
About Seer
關於Seer
(Get Rating)
(獲取評級)
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
SEER,Inc.是一家生命科學公司,致力於開發和商業化產品,以破譯蛋白質組的祕密。它開發了蛋白質圖譜產品套件,這是一種集成的解決方案,包括消耗品、自動化儀器和軟件,使研究人員能夠在治療和診斷研究以及臨牀試驗中進行蛋白質組研究。該公司打算將其產品用於研究目的,包括學術機構、生命科學和研究實驗室,以及用於非診斷和非臨牀目的的生物製藥和生物技術公司。它與探索生命科學有限責任公司達成了一項合作協議。和索爾克生物研究所。該公司前身為Seer Biosciences,Inc.,於2018年7月更名為Seer,Inc.。SEER,Inc.成立於2017年,總部位於加利福尼亞州雷德伍德城。
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
接受《復仇者日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Avantor和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧